vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
15.33
+1.30 (9.27%)
Aug 14, 2025, 11:16 AM - Market open
vTv Therapeutics Employees
vTv Therapeutics had 23 employees as of December 31, 2024. The number of employees increased by 7 or 43.75% compared to the previous year.
Employees
23
Change (1Y)
7
Growth (1Y)
43.75%
Revenue / Employee
$739
Profits / Employee
-$850,217
Market Cap
109.84M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 23 | 7 | 43.75% |
Dec 31, 2023 | 16 | 3 | 23.08% |
Dec 31, 2022 | 13 | 4 | 44.44% |
Dec 31, 2021 | 9 | -16 | -64.00% |
Dec 31, 2020 | 25 | -1 | -3.85% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VTVT News
- 1 day ago - vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 days ago - vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin - GlobeNewsWire
- 7 days ago - vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes - GlobeNewsWire
- 2 months ago - vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewsWire
- 3 months ago - vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin - GlobeNewsWire
- 3 months ago - vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes - GlobeNewsWire
- 5 months ago - vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewsWire